<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: Use of the second-generation antipsychotic drugs (SGAs) results in the development of <z:hpo ids='HP_0001513'>obesity</z:hpo> and a type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>-like syndrome </plain></SENT>
<SENT sid="1" pm="."><plain>We hypothesised that, in addition to the <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> associated with the <z:hpo ids='HP_0001513'>obesity</z:hpo>, the SGAs might have <z:hpo ids='HP_0011009'>acute</z:hpo> effects on <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism that could contribute to the derangements in <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We investigated the effects of therapeutically relevant levels of three different antipsychotic medications (<z:chebi fb="6" ids="5613">haloperidol</z:chebi>, <z:chebi fb="0" ids="8707">quetiapine</z:chebi> and <z:chebi fb="35" ids="3766">clozapine</z:chebi>) on <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance, measures of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and hepatic <z:chebi fb="105" ids="17234">glucose</z:chebi> production, and on insulin and glucagon secretion in rats </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: We found that these drugs induce <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> in rats that is associated with <z:mp ids='MP_0003058'>increased insulin secretion</z:mp> (<z:chebi fb="35" ids="3766">clozapine</z:chebi>&gt;<z:chebi fb="0" ids="8707">quetiapine</z:chebi>&gt;<z:chebi fb="6" ids="5613">haloperidol</z:chebi>) but is independent of <z:mp ids='MP_0005456'>weight gain</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>However, Akt/protein kinase B activation is <z:mpath ids='MPATH_458'>normal</z:mpath>, and at these levels of drug there was no effect on insulin action in fat cells or soleus muscle, and no effect on insulin sensitivity as evaluated by insulin tolerance tests </plain></SENT>
<SENT sid="5" pm="."><plain>We show that <z:chebi fb="35" ids="3766">clozapine</z:chebi> induces <z:mp ids='MP_0005559'>increased glucose levels</z:mp> following <z:chebi fb="1" ids="15361">pyruvate</z:chebi> and <z:chebi fb="3" ids="17754">glycerol</z:chebi> challenges, indicating an increase in hepatic <z:chebi fb="105" ids="17234">glucose</z:chebi> output (HGO) </plain></SENT>
<SENT sid="6" pm="."><plain>Increased HGO would in turn increase insulin release and would explain the apparent phenotype mimicking <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>We provide evidence that this effect could at least in part be mediated by a stimulation of glucagon secretion </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS/INTERPRETATION: Our findings indicate that SGAs can cause <z:hpo ids='HP_0011009'>acute</z:hpo> derangements in <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism that are not caused by a direct induction of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> but act via an increase in glucagon secretion and thus stimulation of hepatic <z:chebi fb="105" ids="17234">glucose</z:chebi> production </plain></SENT>
</text></document>